Usefulness of Serum Leucine-rich Alpha 2 Glycoprotein in Crohn's Disease: Is There Any Difference between Small Intestine and Colonic Lesions?

被引:0
|
作者
Matsumoto, Satohiro [1 ]
Mashima, Hirosato [1 ]
机构
[1] Jichi Med Univ, Dept Gastroenterol, Saitama Med Ctr, 1-847 Amanuma, Saitama, Saitama 3308503, Japan
关键词
leucine-rich alpha-2 glycoprotein; cutoff value; delta value; mucosal healing; small intestine; Crohn's disease; INFLAMMATORY BOWEL DISEASES; FECAL CALPROTECTIN; ENDOSCOPIC ACTIVITY; MAGNETIC-RESONANCE; BIOMARKER; LACTOFERRIN; MARKER; SCORE; CRP;
D O I
10.1093/crocol/otad028
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Lay Summary The superiority of leucine-rich alpha 2 glycoprotein (LRG) to C-reactive protein (CRP) differs between small intestinal and colonic lesions. For Crohn's disease patients with ileum-dominant activity, monitoring of both LRG and CRP is necessary, instead of monitoring CRP alone. Background The usefulness of leucine-rich alpha 2 glycoprotein (LRG) to evaluate Crohn's disease (CD) activity differs among various intestinal lesions. We aimed to evaluate the association between endoscopic disease activity based on the Simple Endoscopic Score for Crohn's disease (SES-CD) and LRG level separately for small intestinal and colonic lesions. Methods We examined the correlation between LRG level and SES-CD and performed receiver operating characteristic (ROC) analysis to determine the LRG cutoff value in 141 patients who underwent endoscopy (total 235 measurements). Furthermore, the LRG cutoff value was analyzed by comparing small intestinal and colonic lesions. Results LRG levels were significantly higher in patients without mucosal healing than in those with mucosal healing (15.9 mu g/mL vs 10.5 mu g/mL, P < .0001). The LRG cutoff value for mucosal healing was 14.3 mu g/mL (area under the ROC curve [AUC]: 0.80; sensitivity: 0.89; specificity: 0.63). The LRG cutoff value for patients with type L1 was 14.3 mu g/mL (sensitivity: 0.91; specificity: 0.53), and that for patients with type L2 was 14.0 mu g/mL (sensitivity: 0.95; specificity: 0.73). The diagnostic performance (AUC) of LRG and C-reactive protein (CRP) for mucosal healing was, respectively, 0.75 and 0.60 (P = 0.01) in patients with type L1 and 0.80 and 0.85 (P = 0.90) in patients with type L2. Conclusions The optimal LRG cutoff value for evaluating mucosal healing in CD is 14.3 mu g/mL. LRG is more useful than CRP for predicting mucosal healing in patients with type L1. The superiority of LRG to CRP differs between small intestinal and colonic lesions.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate small intestinal mucosal healing in asymptomatic CRP-negative Crohn's disease
    Tanaka, A.
    Kanmura, S.
    Maeda, N.
    Kuwazuru, K.
    Komaki, F.
    Komaki, Y.
    Ido, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 775 - 775
  • [22] Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn's disease during biological remission
    Nakamura, Naohiro
    Honzawa, Yusuke
    Ito, Yuka
    Sano, Yasuki
    Yagi, Naoto
    Kobayashi, Sanshiro
    Aoi, Mamiko
    Tomiyama, Takashi
    Tahara, Tomomitsu
    Fukata, Norimasa
    Fukui, Toshiro
    Naganuma, Makoto
    INTESTINAL RESEARCH, 2024,
  • [23] Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn's disease during biological remission
    Nakamura, Naohiro
    Honzawa, Yusuke
    Ito, Yuka
    Sano, Yasuki
    Yagi, Naoto
    Kobayashi, Sanshiro
    Aoi, Mamiko
    Tomiyama, Takashi
    Tahara, Tomomitsu
    Fukata, Norimasa
    Fukui, Toshiro
    Naganuma, Makoto
    INTESTINAL RESEARCH, 2024,
  • [24] Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease
    Yoshimura, Tetsuhiro
    Mitsuyama, Keiichi
    Sakemi, Ryosuke
    Takedatsu, Hidetoshi
    Yoshioka, Shinichiro
    Kuwaki, Kotaro
    Mori, Atsushi
    Fukunaga, Shuhei
    Araki, Toshihiro
    Morita, Masaru
    Tsuruta, Kozo
    Yamasaki, Hiroshi
    Torimura, Takuji
    MEDIATORS OF INFLAMMATION, 2021, 2021
  • [25] Usefulness of the Optimal Cutoff Value and Delta Value of Leucine-Rich Alpha 2 Glycoprotein in Ulcerative Colitis
    Matsumoto, Satohiro
    Mashima, Hirosato
    CROHNS & COLITIS 360, 2022, 4 (04)
  • [26] LEUCINE-RICH ALPHA 2 GLYCOPROTEIN: A USEFUL BIOMARKER TO DISCRIMINATE SMALL INTESTINAL MUCOSAL HEALING IN C-REACTIVE PROTEIN-NEGATIVE CROHN'S DISEASE
    Tanaka, Akihito
    Kanmura, Shuji
    Maeda, Nobuhisa
    Kuwazuru, Kosuke
    Komaki, Fukiko
    Komaki, Yuga
    Ido, Akio
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S20 - S21
  • [27] Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis
    Shinzaki, Shinichiro
    Matsuoka, Katsuyoshi
    Iijima, Hideki
    Mizuno, Shinta
    Serada, Satoshi
    Fujimoto, Minoru
    Arai, Norimitsu
    Koyama, Noriyuki
    Morii, Eiichi
    Watanabe, Mamoru
    Hibi, Toshifumi
    Kanai, Takanori
    Takehara, Tetsuo
    Nakad, Tetsuji
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (01): : 84 - 91
  • [28] Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis
    Shinzaki, Shinichiro
    Matsuoka, Katsuyoshi
    Iijima, Hideki
    Mizuno, Shinta
    Serada, Satoshi
    Watanabe, Mamoru
    Hibi, Toshifumi
    Kanai, Takanori
    Takehara, Tetsuo
    Naka, Tetsuji
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 164 - 165
  • [29] Serum leucine-rich alpha-2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan
    Yasuda, Ryosuke
    Arai, Katsuhiro
    Kudo, Takahiro
    Nambu, Ryusuke
    Aomatsu, Tomoki
    Abe, Naoki
    Kakiuchi, Toshihiko
    Hashimoto, Kunio
    Sogo, Tsuyoshi
    Takahashi, Michiko
    Etani, Yuri
    Kato, Ken
    Yamashita, Yushiro
    Mitsuyama, Keiichi
    Mizuochi, Tatsuki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (07) : 1131 - 1139
  • [30] Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn's disease activity confirmed by balloon-assisted enteroscopy
    Kawamoto, Ami
    Takenaka, Kento
    Hibiya, Shuji
    Kitazume, Yoshio
    Shimizu, Hiromichi
    Fujii, Toshimitsu
    Saito, Eiko
    Ohtsuka, Kazuo
    Okamoto, Ryuichi
    INTESTINAL RESEARCH, 2024, 22 (01) : 65 - 74